The program builds on NSW Health’s Medical Device Commercialisation Training Program, also delivered by Cicada Innovations, which nurtured a series of revolutionary medtech innovations such as Tetratherix’s (formerly Trimph) “bone glue”, and Beyond 700’s tear film that is currently being used by NASA.
Brownyn Le Grice, CEO of ANDHealth, says “Australia has exceptional health and medical research capabilities but continues to struggle with commercialisation. Programs that provide specialised support and access to a diverse ecosystem of executives and industry leaders - such as those run by ANDHealth and Cicada Innovations - have been proven to accelerate commercialisation outcomes.
“We congratulate NSW Health for its focus on building the capabilities required to grow a robust medical technology industry that will drive both economic and health outcomes for its residents. We are delighted to work alongside our long-time partner Cicada Innovations who share ANDHealth’s vision and commitment to building a collaborative innovation ecosystem in NSW.”
Sally-Ann Williams, CEO of Cicada Innovations, says, “We are thrilled to be delivering the NSW Health Commercialisation Training Program which will drive meaningful innovation and commercialisation outcomes for medical technology innovators. Collaborations are key to building a thriving ecosystem so it is a privilege to be partnering with ANDHealth, one of the leaders in digital health, whose involvement not only strengthens the program but enables us to have an even greater impact in the healthcare sector.”
ANDHealth’s unique commercialisation programs span the entire development and commercialisation pathway from idea to exit for innovators creating evidence-based digital health technologies in Australia. Since its inception in 2017, ANDHealth has worked with over 450 digital health companies, providing well over 1500 hours of support, education and coaching. In the last three years, cohort companies from the ANDHealth+ incubator have gone on to raise $42.7 million of new funds (dilutive and non-dilutive), generated $26.7 million in new revenues, and created 265 new jobs (FTEs).
Recruitment for the MDCTP Program has begun and aims to attract a wide variety of medical device technologists, clinicians, postdoctoral researchers, and medtech and biotech entrepreneurs.